Cellectis and Lonza achieve significant milestone on CHO-K1SV GS knock-out

21 July 2011

Cellectis bioresearch, the genome customization specialist and a commercial subsidiary of French biotech firm Cellectis (Alternext: ALCLS), and Switzerland’s Lonza (SIX: LONN) have reached a significant milestone in the development of a newly bioengineered cell line. Details of the payment from Lonza triggered by this milestone were not disclosed.

Using its proprietary meganuclease technology, Cellectis bioresearch successfully managed to deactivate ("knock-out") the cell-based glutamine synthetase (GS) in CHO-K1SV, Lonza's proprietary host cell line. This achievement comes as part of an overall strategic plan to further advance the GS Gene Expression System offering and is expected to contribute to shortened development timelines critical for the early phases of bioproduction.

"We are very pleased to deliver Lonza's engineered cell line ahead of time and to demonstrate the great potential of meganucleases for knock-outs in the bioproduction field," said Christophe Delenda, chief scientific officer of Cellectis bioresearch.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology